Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/20/2016Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Signs Exclusive Partnership to Expand Blood Lead Testing in China
CINCINNATI, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its Magellan Diagnostics business unit has signed an exclusive distribution agreement with MedCaptain Medical Technology Co., Ltd. (MedCaptain, www.medcaptain.com/en/), a leading innovator in the fields of infusion management, in-vitro diagnostics, and rehabilitation care in the Chinese market.  Magellan Diagnostics’ LeadCare® II blood lead testing system is the only FDA and CFDA cleared,... 
 Printer Friendly Version
11/10/2016Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2017 Cash Dividend Rate, and Reaffirms Fiscal 2017 Guidance
GENERAL HIGHLIGHTS CINCINNATI, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fourth quarter and full-year fiscal 2016 net revenues of $47.0 million and $196.1 million, respectively, flat and an increase of 1%, respectively, from the same periods of the prior fiscal year; reported fourth quarter and full-year fiscal 2016 operating income of $8.9 million and $51.4 million, respectively, decreases of 33% and 8%, respectively, from the same ... 
 Printer Friendly Version
10/18/2016Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2016 Operating Results and Provides Fiscal 2017 Revenue and Earnings Guidance
CINCINNATI, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that based on preliminary results, it expects revenues for fiscal year 2016, ended on September 30, 2016, to be approximately $196 million, an increase of 1% compared to the prior year. Diluted earnings per share are expected to be $0.75 to $0.76, including costs related to acquisition activity and costs associated with the reorganization of Diagnostics sales and marketing leadership (in the a... 
 Printer Friendly Version
10/3/2016Bioline is Certified to the ISO 13485 Quality Standard
CINCINNATI, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) is proud to announce that the London R&D and Berlin manufacturing facilities are now fully accredited to the ISO 13485 quality standard. Bioline recognizes the importance of adhering to a quality management system in the development, manufacture and supply of test components to the molecular diagnostic arena. We are committed to strengthening our r... 
 Printer Friendly Version
9/26/2016Meridian Expands Molecular Test Technology License with Eiken Chemical Co., Ltd.
CINCINNATI, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced it has completed an amendment to the license agreement with Eiken Chemical Co., Ltd., Japan, for its “LAMP” (Loop-mediated Isothermal Amplification) technology for the expanded areas of animal, food and water testing.  The LAMP technology is a leading nucleic acid amplification method that is simple to perform, rapid, highly specific and performed at a single temperature.  Unlike other amplif... 
 Printer Friendly Version
9/20/2016Bioline Launches New SensiFAST™ Lyo-Ready No-ROX Mix
CINCINNATI, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFAST Lyo-Ready No-ROX Mix from Bioline to add to the SensiFAST family of real-time PCR products. Bioline has developed a ready-to-use, lyophilization-compatible qPCR mix, the SensiFAST Lyo-Ready No-ROX Mix. The SensiFAST Lyo-Ready No-ROX Mix has exactly the same fast, highly reproducible performanc... 
 Printer Friendly Version
8/25/2016Meridian Malaria Test Wins Prestigious Innovation Award
illumigene® Malaria Receives 1st Place Award at the  Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris CINCINNATI, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) was awarded 1st place for innovation in emergency treatment and point-of-care testing for its illumigene® Malaria test at the 2016 JIB/ACNBH Conference. Innovations from worldwide companies contributing to the development of the Medical Biology... 
 Printer Friendly Version
8/23/2016Meridian Bioscience Expands Its Portfolio and Launches First Analyte Specific Reagent (ASR) Products
CINCINNATI, Aug. 23, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of their Analyte Specific Reagent (ASR) product line. The first ASR products include a primer set and probes for detection of Helicobacter pylori and the target sequence associated with Clarithromycin-resistant H. pylori strains. Richard L. Eberly, President, Chief Commercial Officer stated, “As a consistent innovator and market share leader for in vitro diagnostic devices, it is... 
 Printer Friendly Version
8/9/2016Magellan Diagnostics Receives CFDA Clearance for LeadCare® II in China
Simple, portable diagnostic instrument used in thousands of US clinics will provide three-minute blood lead testing results to Chinese clinicians and parents CINCINNATI, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced Magellan Diagnostics, a business unit of Meridian Bioscience, has received clearance from the China Food and Drug Administration (CFDA) for its LeadCare II Blood Lead Testing System.  The system is small, portable, and produces a quantit... 
 Printer Friendly Version
7/28/2016Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance
GENERAL HIGHLIGHTS CINCINNATI, July 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fiscal 2016 third quarter and first nine months net revenues of $50.7 million and $149.1 million, respectively, increases of 5% and 1%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $13.7 million, a decrease of 5% from the same period of the prior fiscal year; reported nine months operating inco... 
 Printer Friendly Version
6/15/2016Meridian Bioscience, Inc. Receives FDA Clearance for New Molecular Test for the Detection of Mycoplasma pneumoniae
CINCINNATI, June 15, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene® Mycoplasma Direct assay, launched earlier this year in Europe, features a simplified 3-step procedure. The new procedure will significantly expand Meridian’s customer base by eliminating the need for specialized techniques and training, as well as pr... 
 Printer Friendly Version
6/2/2016Bioline Launches New MyTaq™ Plant-PCR Kit
CINCINNATI, June 02, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq™ Plant-PCR Kit, the latest in the line of kits from Bioline for direct PCR. The MyTaq™ Plant-PCR Kit is the first of many products Bioline is bringing to the agricultural market to advance plant genetic research. Bioline is also developing new technologies to support Agribio companies in their quest... 
 Printer Friendly Version
4/28/2016Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GENERAL HIGHLIGHTS CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., (NASDAQ:VIVO) today: reported fiscal 2016 second quarter and first six months net revenues of $51.3 million and $98.4 million, respectively, decreases of 1% from the same periods of the prior fiscal year; reported second quarter operating income of $15.2 million (including $1.2 million of costs associated with acquisition activity), a decrease of 4% from the same period of the prior fiscal... 
 Printer Friendly Version
4/27/2016Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
illumigene® Mycoplasma Direct provides fast and accurate results in less than 1 hour for immediate and targeted treatment CINCINNATI, April 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene Mycoplasma Direct assay features a simplified procedure compared to the existing illumigene Mycoplasma product. The new procedure... 
 Printer Friendly Version
3/24/2016Meridian Bioscience Acquires Magellan Diagnostics, Inc.
CINCINNATI, March 24, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) announced today that it has completed the acquisition of Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. Headquartered in Billerica, Massachusetts (near Boston), Magellan pioneered the engineering, development and manufacturing of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults. Today, Magellan is the l... 
 Printer Friendly Version
3/3/2016Bioline Launches New EPIK™ miRNA Select Kits
CINCINNATI, March 03, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the EPIK™ miRNA Select Assays, developed for study of individual microRNA (miRNA) molecules. The EPIK miRNA Select Kits compliment the EPIK miRNA Panel Assays released at the end of 2015 and demonstrates the continued collaboration between MiRXES in Singapore and Bioline.  Recent studies continue to show the... 
 Printer Friendly Version
1/27/2016Meridian Bioscience Reports First Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GENERAL HIGHLIGHTS CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported first quarter net revenues of $47.2 million, a decrease of 2% from the same period of the prior fiscal year; reported first quarter operating income of $13.6 million, an increase of 7% from the same period of the prior fiscal year; reported first quarter net earnings of $8.9 million, or $0.21 per diluted share, increases of 13% and 11... 
 Printer Friendly Version
1/26/2016Meridian Bioscience and Lean Continuous Improvements, LLC Collaborate to Apply Lean Principles to Recent Launch of illumigene® Malaria
CINCINNATI, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. announced today that the recent product transfer and launch of its innovative molecular test illumigene® Malaria was accomplished on an accelerated schedule via a collaboration with Lean Continuous Improvements, LLC (LCI).  The development and transfer of medical devices is a complicated and highly regulated process.  Meridian recognized the need to streamline the tasks and activities required to move a new test from the p... 
 Printer Friendly Version
1/26/2016New Malaria Test, illumigene® Malaria, Sets a New Gold Standard for Diagnosis
Meridian Bioscience Collaborates With the Centers for Disease Control and Prevention and Cheikh Anta Diop University of Dakar to Launch Diagnostic Test up to 80,000 Times More Sensitive Than Current Options CINCINNATI, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for illumigene® Malaria, a novel, highly accurate  test developed by Meridian with the technical assistance of the Centers for Disease Control and Preventi... 
 Printer Friendly Version